Insulin-like growth factor 1 differentially regulates estrogen

receptor-dependent transcription at estrogen response element and AP-1 sites in

breast cancer cells. by Cascio, S. et al.
Insulin-like Growth Factor 1 Differentially Regulates Estrogen
Receptor-dependent Transcription at Estrogen Response
Element and AP-1 Sites in Breast Cancer Cells*
Received for publication, June 29, 2006, and in revised form, December 12, 2006 Published, JBC Papers in Press,December 13, 2006, DOI 10.1074/jbc.M606244200
Sandra Cascio‡§, Viviana Bartella‡¶, Cecilia Garofalo¶, Antonio Russo§, Antonio Giordano‡, and Eva Surmacz‡1
From the ‡Sbarro Institute for Cancer Research andMolecular Medicine, Temple University, Philadelphia Pennsylvania 19122,
the §Department of Oncology, University of Palermo, Palermo, Italy 90047, and the ¶Department of Pharmaco-Biology,
University of Calabria, Cosenza, Italy 87036
Cross-talk between insulin-like growth factor 1 (IGF-1) and
estrogen receptor  (ER) regulates gene expression in breast
cancer cells, but the underlying mechanisms remain unclear.
Here, we studied how 17--estradiol (E2) and IGF-1 affect ER
transcriptional machinery in MCF-7 cells. E2 treatment stimu-
lated ER loading on the estrogen response element (ERE) in the
pS2 promoter and on the AP-1motif in the cyclin D1 promoter.
On ERE, similar amounts of liganded ER were found at 1–24-h
time points, whereas on AP-1, ER binding fluctuated over time.
At 1 h, liganded ER was recruited to ERE together with histone
acetyltransferases SRC-1 and p300, ubiquitin ligase E6-AP, his-
tone methyltransferase Carm1 (Carm), and polymerase (pol) II.
This coincided with increased histone H3 acetylation and up-
regulation of pS2mRNA levels. At the same time, E2moderately
increased cyclin D1 expression, which was associated with the
recruitment of liganded ER, SRC-1, p300, ubiquitin ligase
E6-AP (E6L), Mdm2, and pol II, but not other regulatory pro-
teins, to AP-1. In contrast, at 1 h, IGF-1 increased the recruit-
ment of the ERSRC-1p300E6LMdm2Carmpol II complex on
AP-1, but not on ERE, and induced cyclin D1, but not pS2,
mRNA expression. Notably, ER knockdown reduced the associ-
ation of ER, E6L, Mdm2, Carm, and pol II with AP-1 and
resulted in down-regulation of cyclin D1 expression. IGF-1
potentiated the effects of E2 on ERE but not to AP-1 and
increased E2-dependent pS2, but not cyclin D1, mRNA expres-
sion. In conclusion, E2 and IGF-1 differentially regulate ER
transcription at ERE and AP-1 sites.
Breast cancer development and progression depends on
complex cross-talk between steroid hormones (e.g. 17--estra-
diol (E2)2) and growth factors, such as insulin-like growth fac-
tors (IGFs) (1–6). In estrogen receptor  (ER)-positive breast
tumors and cancer cell lines, ER and IGF-1R are often coex-
pressed, andE2 acts in synergywith IGF-1 to stimulatemaximal
cell proliferation (5–7). The mechanism of ER/IGF-1 interac-
tion includes regulation of the IGF-1 system by E2 and modu-
lation of ER-dependent transcription by IGF-1. For instance, E2
stimulates the expression of the IGF-1 receptor, IGF-1 ligands,
and amajor IGF-1R signaling substrate, IRS-1 (6). Reciprocally,
IGF-1 can activate ER in a ligand-independent manner and
potentiate ER-dependent transcription through phosphoryla-
tion of ER coactivators and other ER regulatory proteins
(8–12). These effects are balanced by down-regulation of ER
expression (13) in response to IGF-1 stimulation (14, 15) and
estrogen independence that occurs in cells overexpressing
IGF-1R or IRS-1 (6).
On a genetic level, the interaction between ER and IGF-1 has
been shown to affect the expression of E2-responsive genes,
including genes whose transcription is directly regulated by ER
(e.g. pS2) and those modulated by ER indirectly (e.g. a key cell
cycle regulator, cyclin D1) (16–19).
In the case of pS2, activated ER induces transcription by
directly binding to estrogen response elements (EREs) in the
promoter. Recent studies suggested that liganded ER is
recruited to pS2 ERE sites in an ordered and cyclical fashion
together with several other cofactors, including coactivators of
the p160 family (SRC1 and p/CIP); other histone acetyltrans-
ferases (e.g. p300, CBP, and p/CAF); histone methyltransferases
(e.g. Carm); polymerase (pol) II; general transcription factors (e.g.
pol II transcription factors andTATA-binding protein-associated
factors); histones H3 and H4; nucleosome remodeling proteins
SWI/SNF,p68RNAhelicase, andTRAP-mediator complexes that
stimulate pol II; and many other chromatin-modifying enzymes
(20,21).ThedynamicsofERtranscriptional complexassemblyhas
beenwell characterized for the period 1–3 h following E2 stimula-
tion (21–24). Although it has been reported that IGF-1 can influ-
ence pS2 expression (25), it is not knownwhether IGF-1 can affect
ER complex assembly on the pS2 ERE site.
Cyclin D1 is a key cell cycle regulator, often coexpressedwith
ER in breast cancer (26–29). E2 has been shown to stimulate
cyclin D1 mRNA transcription through indirect interaction
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with several regulatory regions in the promoter, such as binding
motifs forAP-1 (30) and cAMP-response element and SP-1 (31)
motifs. The exact mechanism of ER binding and the composi-
tion of ER transcriptional complex at these indirect sites remain
unclear. AtAP-1 sites, ERmight interactwithDNA through the
AP-1 complex (i.e. through Jun protein) or interact with AP-1
through SRC/histone acetyltransferase (32–35).
IGF-1 is known to modulate AP-1 activity in breast cancer
cells (36, 37) and to stimulate cyclin D1 transcription and
enhance cyclin D1 mRNA stability and protein levels (38–40).
There is also evidence that cyclinD1 activity is regulated by cross-
talk between E2 and IGF-1 pathways. For instance, IGF-1 is
required for cyclin D1 nuclear accumulation in E2-stimulated
MCF-7 cells (41). Furthermore, IGF-1-induced cyclin D1 expres-
sion in MCF-7 breast cancer cells depends on the presence of ER
(38, 42, 43).However, theeffectsof IGF-1on the recruitmentofER
and other transcriptional modulators to transcription regulation
sites in the cyclin D1 promoter are unknown.
In this study, we explored using in vitro and in vivo tech-
niques how E2, IGF-1, and the combination of both factors
regulate ER nuclear translocation, ER recruitment to the pS2
ERE and cyclin D1 AP-1 motifs, and ER complex assembly at
these sites.We also assessed how ER knockdown affects IGF-1-
dependent transcriptional regulation of cyclin D1 expression.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments—MCF-7 cells were routinely
grown in Dulbecco’s modified Eagle’s medium/F-12 (both from
Invitrogen) containing5%calf serum.70%confluent cultureswere
synchronized in phenol red-free serum-free medium (SFM) for
24 h (44, 45) and then stimulatedwith 10 nME2 (Sigma), 50 ng/ml
IGF (Bachem), or a combination of bothmitogens.
Western Blotting (WB)—Synchronized cells were stimulated
with E2 and/or IGF-1 for 1 and 4 h. Cytoplasmic and nuclear
protein lysates were obtained as described previously (46). Pro-
tein expression was analyzed using 50 g of cytoplasmic cell
lysates or 100 g of nuclear lysates. The following antibodies
(Abs) were used: anti-ER F-10 monoclonal antibody (mAb)
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-
GAPDH mAb (Research Diagnostics Inc.), and anti-nucleolin
mAb (Santa Cruz Biotechnology).
DNA Affinity Precipitation Assay (DAPA)—Binding of
nuclear ER to ERE and AP-1 DNA motifs was assessed in vitro
using a modified DAPA protocol of Zhu et al. (47). Briefly,
nuclear extracts were obtained from cells stimulated with E2
and/or IGF-1 for 1 h. 70g of nuclear proteins weremixedwith
2 g of specific biotinylated DNA probes (see below) in 400 l
of BufferD (20mMHEPES, pH7.9, 10% glycerol, 50mMKCl, 0.2
mM EDTA, 1.5 mM MgCl2, 10 mM ZnCl2, 1 mM dithiothreitol,
and 0.25% Triton X-100) and then incubated on ice for 45 min.
After that, 50 l of streptavidin-agarose beads (Invitrogen)
were added, and the samples were agitated for 2 h at 4 °C. Next,
the agarose beads-protein complexes were collected by brief
centrifugation and washed twice in Buffer D. Proteins were
uncoupled from DNA probes by the addition of 40 l of SDS
loading buffer and heating at 96 °C for 10min. After removal of
the beads, the supernatants were analyzed by WB for the pres-
ence of ER. The DNAmotif probes were prepared by annealing
a biotinylated sense oligonucleotide (for ERE, 5-Bio-CCC-
CTGCAAGGTCACGGTGGCCACCCCGTGA-3; for AP-1,
5-Bio-TTAAAAAAAATGAGTCAGAATGGAGATCACT-
3) with nonbiotinylated antisense oligonucleotide (for ERE, 5-
TCACGGGGTGGCCACCGTGACCTTGCAGGGG-3; for
AP-1, 5-AGTGATCTCCATTCTGACTCATTTTTTTTAA-
3). Unlabeled probes were used as negative controls. As an
additional control, a 10-fold excess of unlabeled probes was
added to the nuclear lysates 30 min prior to the addition of the
labeled probes to block specific probe-protein interactions.
Chromatin Immunoprecipitation Assay (ChIP)—80% con-
fluent cultures of MCF-7 cells were shifted to SFM for 24 h and
then treatedwith 2.5M-amanitin for 2 h. Then the cells were
stimulatedwith 10 nME2 and/or 50 ng/ml IGF for 1–24 h or left
untreated in SFM. Next, the cells were cross-linked with
paraformaldehyde, and soluble chromatin was obtained as
described by us before (48). The specific DNA-protein com-
plexes were immunoprecipitated (IP) from soluble chromatin
with the following Abs: anti-ER C terminus mAb F-10 (Santa
Cruz Biotechnology) for ER; anti-pol II CTD4H8mAb for pol II
(UBI); and anti-p300 (UBI), anti-H3 (UBI), anti-E6L (UBI),
anti-Mdm2 (Calbiochem), anti-Carm (UBI), and anti-SRC1
1135 mAb for SRC1 (UBI). The presence of specific DNA
motifs in the precipitates was detected by PCR. The ERE-con-
taining pS2 promoter fragment was amplified using the fol-
lowing primers: forward, 5-GATTACAGCGTGAGCCA-
CTG-3; reverse, 5-TGGTCAAGCTACATGGAAGG-3.
The AP-1 site in the cyclin D1 promoter was amplified using
the following primers: forward, 5-GAGGGGACTAATAT-
TTCCAGCAA-3; reverse, 5-TAAAGGGATTTCAGCTT-
AGCA-3. The primers for GAPDH promoter were as
follows: forward, 5-GCTACTAGCGGTTTTACGGG-3;
reverse, 5-AAGATGCGGCTGACTGTCGAA-3. The PCR
conditions for pS2 andGAPDHpromoters were 1min at 94 °C,
1min at 58 °C, and 50 s at 72 °C for 28 cycles, and conditions for
cyclin D1 promoter were 45 s at 94 °C, 40 s at 58 °C, and 90 s at
72 °C for 35 cycles. In control samples, nonimmune IgG (rabbit
for IRS-1 Abs andmouse for all other Abs; Santa Cruz Biotech-
nology) was used instead of the primary Abs.
Quantitative Real Time PCR—Synchronized MCF-7 cells
were treated for 1 h and 4 h with 10 nM E2 and/or 50 ng/ml
IGF-1. Total cellular RNA was isolated using TRIzol reagent
(Invitrogen). 2 g of total RNA was reverse transcribed using
the TaqMan reverse transcription kit (ABI) according to the
vendor’s instructions. 2 l of reverse transcription products
were used to detect pS2 and cyclin D1DNA. For pS2, we used
the following primers: forward, 5-GGTCGCCTTTGGAG-
CAGAG-3; reverse, 5-AGGACCAGGGCGCAGATC-3;
probe, 5-6-carboxyfluorescein-AGGCAATGGCCACCAT-
GGAGAACAA-tetramethyl-6-carboxyrhodamine-3. For
cyclin D1, we used the following primers: forward, 5-ACCTG-
AGGAGCCCCAACAA-3; reverse, 5-TCTGCTCCTGGCA-
GGCC-3; probe, 5-6-carboxyfluorescein-TCCTACTACCG-
CCTCACACGCTTCCTC-tetramethyl-6-carboxyrhodamine-
3. To normalize quantitative real time PCR, parallel TaqMan
assays were run on each sample for the -actin housekeeping
gene. Changes in the pS2 and cyclin D1mRNA content relative
to -actin mRNA levels were determined using the compara-
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tive CT method (64) to calculate changes in CT and ultimately
-fold and percentage change. An average CT value for each
RNA was obtained for replicate reactions.
ER Knockdown—ER expression in MCF-7 cells was reduced
using the ERSMARTpool siRNA (Dharmacon). ER siRNA (500
nM) was mixed with the transfection agent RNAiFect (Qiagen)
(siRNA/RNAiFect ratio 1:3), incubated for 15min at room tem-
perature, and then transfected into 70% confluent cultures of
MCF-7 cells. After 6 h, the cells were placed in SFM for 24 h and
then treatedwith 50 ng/ml IGF for 1 h. The nontargeting siRNA
number 2 (Dharmacon) was used as a control in all ER siRNA
experiments.
RESULTS
IGF-1 Increases Nuclear Translocation of Liganded ER in
MCF-7 Cells—We have previously observed efficient nuclear
translocation of ER in response to E2 treatment (1–24 h) in
MCF-7 breast cancer cells (48). Since IGF-1 is known to activate
ER in a ligand-independent manner (6, 49–51), we assessed
whether IGF-1 alone can stimulate ER nuclear transport and
whether it can potentiate E2-induced ER translocation.
To test this, we analyzed ER protein abundance in cytoplasmic
and nuclear protein lysates obtained fromMCF-7 cells stimulated
with E2, IGF-1, or E2 plus IGF-1 for 1 or 4 h (Fig. 1). In unstimu-
lated cells (SFM), higher levels of ER were found in the cytoplasm
than in the nucleus. As expected, E2 treatment significantly
increased nuclear abundance of ER, decreasing ER cytoplasmic
levels (Fig. 1). This effect was apparent at 1 and 4 h of stimulation.
IGF-1 alone stimulatedmodest nuclear translocation of unli-
ganded ER, especially at 4 h of treatment. The addition of IGF-1
potentiated nuclear transport of liganded ER at 4 h but not at
1 h of treatment (Fig. 1).
E2 and IGF-1 Differentially Regulate Dynamics of pS2 and
CyclinD1mRNAExpression—Since E2 and IGF-1 differentially
affected nuclear accumulation of ER (Fig. 1), we hypothesized
that the two factorsmight exert diverse effects on the transcrip-
tion of ER-regulated genes, such as pS2 and cyclin D1. pS2
mRNA levels were significantly induced by E2 at 1 and 4 h and
modestly up-regulated by IGF-1 at 4 h. The addition of IGF-1
significantly improved E2-induced pS2 mRNA expression at
1 h (Fig. 2). On the other hand, the expression of cyclin D1
mRNA was significantly augmented by IGF-1 at 1 and 4 h and
moderately induced by E2 treatment at these time points. Inter-
estingly, IGF-1-induced cyclinD1RNAexpressionwas reduced
in the presence of E2.
E2 and IGF-1 Differentially Stimulate ER Binding to ERE and
AP-1 Motifs—Next, we tested whether E2, IGF-1, and E2 plus
IGF-1 differentially regulate ER loading on the EREmotif in the
pS2 promoter and on the AP-1 site in the cyclin D1 promoter
(Fig. 3). The experiments were performed using a DAPA assay,
where short biotinylated DNA probes containing the pS2 ERE
or cyclin D1AP-1 sequences were hybridized with nuclear pro-
teins obtained fromMCF-7 cells stimulated with E2, IGF-1, or
E2 plus IGF-1 for 1 or 4 h. The presence of ER in the resulting
probe-protein complexes was assessed by WB.
We found that E2 induced efficient ER association with both
ERE and AP-1 motifs, whereas IGF-1 moderately increased ER
association with AP-1 but had only minor (albeit significant)
stimulatory effects on ER binding to ERE. Interestingly, IGF-1
increased E2-dependent association of ER to ERE but not to
AP-1 (Fig. 3). The results were similar for 1 and 4 h of treat-
ments (Fig. 3 and data not shown).
E2 and IGF-1 Differentially Induce ER Recruitment to pS2
EREandCyclinD1AP-1 Sites—After ascertaining that liganded
and unliganded ER binds pS2 ERE and cyclin D1 AP-1
sequences in vitro, we examined ER recruitment to thesemotifs
in vivo using ChIP assays. Because the association of ER with
specific chromatin regions might occur with different dynam-
ics than binding of ER with isolated DNA oligonucleotides (as
in DAPA), we analyzed ER association with ERE and AP-1 sites
over the 0–24-h time course (Fig. 4).
FIGURE1.Subcellular localizationofER inE2-and/or IGF-1-treatedMCF-7
cells.MCF-7 cells synchronized in SFMwere treated with 10 nM E2 and/or 50
nM IGF-1 for 1 and 4 h or were left untreated (C). The expression of ER (67
kDa), nucleolin (Nuc;39 kDa), and GAPDH (36 kDa) was assessed byWB in
50 g of cytoplasmic protein lysates or 100 g of nuclear protein lysates, as
described under “Experimental Procedures.” The expression of GAPDH and
nucleolin were used as controls of cytoplasmic and nuclear protein loading,
respectively. The graphs represent relative abundance of nuclear ER under
different conditions. Nuclear levels of ER were normalized to the expression
of nucleolin (relative value 1).
FIGURE 2. pS2 and cyclin D1 mRNA expression under different treat-
ments.MCF-7 cells were treated with E2 and or IGF-1 for 1 and 4 h, and the
abundanceof pS2 and cyclinD1mRNAwas assessedbyquantitative real time
PCR, as described under “Experimental Procedures.” The mRNA levels were
normalized to the expression of -actin mRNA.
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E2 stimulated ER recruitment to
pS2 ERE at 1, 4, 8, 16, and 24 h, with
no significant differences seen over
the time course. The addition of
IGF-1 significantly improved the
binding of liganded ER to ERE at 1
and 4 h but dramatically decreased
ER abundance on ERE at 24 h. The
maximum binding of ER to ERE in
the presence of IGF-1 alone was
noted at 8 h, with modest effects
seen at 1, 4, and 16 h.At 24 h, ERwas
absent from ERE under IGF-1 treat-
ment (Fig. 4).
In contrast, the recruitment of
liganded ER to cyclin D1 AP-1 fluc-
FIGURE 3. ER interacts with the pS2 ERE and cyclin D1 AP-1motifs in vitro.MCF-7 cells were synchronized
in SFMand treatedwith E2 and/or IGF-1 for 1 h, as describedunder “Experimental Procedures.” Nuclear protein
lysates were hybridized with biotinylated DNA probes corresponding to the pS2 ERE consensus sequence or
the cyclin D1 AP-1motif, as detailed under “Experimental Procedures.” ER bound to the ERE or AP-1 probewas
detected by WB. In control experiments (C), the lysates were hybridized with unlabeled probes.
FIGURE 4. Time course of ER association with the pS2 ERE and cyclin D1 AP-1 motifs in vivo. Soluble chromatin was isolated from MCF-7 cells
stimulated with E2, IGF-1, and E2 plus IGF-1 for 1, 4, 8, 16, and 24 h and from untreated cells (SFM). ER ChIP experiments were performed as described
under “Experimental Procedures.” DNA recovered from ER immune complexes was tested for the presence of the pS2 ERE promoter sequences (pS2 ERE)
and the cyclin D1 AP-1 motif (cyclin D1 AP-1) by PCR with specific primers listed under “Experimental Procedures.” In control experiments, the specific
ER Ab was replaced by nonimmune IgG. The abundance of pS2 promoter sequences in all samples before immunoprecipitation is shown as control of
input DNA.
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tuated over time, with the maximal
association seen at 4, 16, and 24 h.
The addition of IGF-1 significantly
reduced the binding of liganded ER
at 16 and 24 h. Under IGF-1 alone,
modest binding of ER to AP-1 was
found at all time points, with the
maximum observed at 4 h (Fig. 4).
E2 and IGF-1 Synergize in the
Recruitment of Several ER-associ-
ated Proteins to the pS2 ERE Site
—Next, we studied how E2 and
IGF-1 treatments affect association
of various ER regulators/chroma-
tin-modulating proteins to ERE and
AP-1 sites (Fig. 5). We focused on
p300, SRC-1, E6L, Mdm2, Carm,
and pol II as well as acetylated his-
tone H3 (AcH3), all of which are
known to play a significant role in
ER transcriptional activity (22, 52,
53). The experiments were per-
formed at 1 and 4 h to address dif-
ferential ER binding to ERE and
AP-1 observed at these time points
(Figs. 3 and 4).
In agreement with published
observations regarding E2-regu-
lated transcription, we observed
variable association of several
ER-associated proteins on ERE and
AP-1 sites (21, 53, 54). On ERE, 1 h
of E2 treatment stimulated the
recruitment of SRC-1, p300, E6L,
Carm, and pol II and increased H3
acetylation. At 4h, the patternof sev-
eral associated proteins was similar,
but the binding of p300 increased,
whereas the recruitment of SRC-1
and the abundance of AcH3
decreased.Theadditionof IGF-1aug-
mented the abundance of liganded
ER, p300, Carm, pol II, and AcH3.
These IGF-1 effects were not seen at
4 h of treatment (Fig. 5A).
In response to 1 h IGF-1 alone,
increased binding was seen for
SRC-1, E6L, and AcH3; however,
the abundance of these proteins was
generally lower relative to that seen
with E2. At 4 h of IGF-1 treatment, Carm II and pol II amounts
increased, whereas E6L decreased (Fig. 5A). Interestingly, lon-
ger exposure to IGF-1 increased the presence of some regulatory
proteins like SRC-1, Carm, pol II, and AcH3 relative to that at 1 h
(Fig. 5A).
E2 and IGF-1 Differentially Recruit ER and Associated Pro-
teins to the AP-1CyclinD1 Site—The effects of E2 and IGF-1 on
the recruitment of ER and different ER transcriptional regulators
to cyclin D1AP-1 differed from that observed for ERE. For exam-
ple, at 1 h, E2 stimulated the binding of Mdm2, but not Carm, to
AP-1. Similarly, at variance with ERE, IGF-1 alone induced the
loading of p300, SRC-1, E6L, Mdm2, Carm, and pol II on this site
(Figs. 5B and 7A).
Synergistic action of E2 and IGF-1 was observed only for
E6L at 1 h and for Mdm2 and Carm at 4 h, whereas other
regulators responded to either E2 or IGF-1 (Figs. 5B and 7A).
FIGURE 5. Identification of ER transcriptional cofactors and modulators recruited to the pS2 ERE and
cyclinD1AP-1 sites in vivo.ChIP assays determining the recruitment of ER, p300, SRC-1 (SRC), E6-APubiquitin
ligase (E6L), acetylatedhistonesH3 (Ac-H3), E3ubiquitin ligaseMdm2 (mdm), histonemethyltransferaseCarm1
(carm), and pol II to the pS2 ERE sequence (A) and to the AP-1 cyclin D1motif (B) at 1 and 4 h of treatment with
E2 and/or IGF-1 were performed as described under “Experimental Procedures.” In Fig. 4A, ChIP for the rapidly
cycling SRC-1 coactivatorwas done at 45min, as described in Ref. 21. In control experiments, the specific ERAb
was replaced by nonimmune IgG (IgG).
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Notably, IGF-1 alone was more efficient than E2 in the
recruitment of several transcriptional regulatory proteins to
AP-1, especially at 4 h of treatment (Fig. 5B).
ER Knockdown Inhibits Transcription of Cyclin D1 at the
AP-1 Site—To examine the role of ER in IGF-1-dependent
cyclin D1 transcription, we inhibited ER expression using RNA
interference technology (Fig. 6). The 80% reduction of ER
protein levels resulted in the inhibition of basal pS2 transcrip-
tion (data not shown) and significantly decreased IGF-1-de-
pendent cyclin D1 mRNA expression (Fig. 6). The latter coin-
cided with significantly reduced loading of ER, E6L, Mdm2,
Carm, and pol II, but not p300 and SRC-1, on the cyclin D1
AP-1 site. In contrast, in cells
treated with nontargeting siRNA,
ER levels and IGF-1-dependent
cyclin D1 transcriptional regulation
resembled that in untransfected
cells stimulatedwith IGF-1 (Figs. 5B
and 6).
DISCUSSION
Cross-talk between ER and
IGF-1 signaling systems has been
shown to regulate several functions
in breast cancer cells, including pro-
liferation, survival, transformation,
migration, cell-cell and cell-surface
adhesion, and invasion (5, 6, 55).
However, molecular mechanisms
involved in ER/IGF-1 interaction
are largely unknown. Here we stud-
ied how IGF-1 affects the associa-
tion of liganded and unliganded ER
with specific ER-responsive gene
promoter motifs and corecruitment
of ER regulatory proteins/DNA
modulators to these sites. We also
assessed the role of ER in IGF-1-in-
duced transcription.We focused on
gene regulatory domains that are
ER- and/or IGF-1-responsive, spe-
cifically the ERE element in the pS2
gene promoter (region 405 to
394) that is a classic site of direct
ER regulation (20, 21, 23, 48, 52) and
the AP-1 binding motif (region
1071 to 931) in the cyclin D1
promoter that is known to be mod-
ulated by IGF-1 and indirectly by ER
(32, 33, 56). In our cell model, only
this cyclin D1 ER-responsive region
was coregulated by E2 and IGF-1 in
vivo, whereas others (e.g. SP-1) were
activated only by E2 (data not
shown).
Our studies yielded several
novel findings that can be summa-
rized as follows. 1) In MCF-7
breast cancer cells, IGF-1 improved ER nuclear transloca-
tion. 2) IGF-1 potentiated binding of liganded ER to the pS2
ERE site but not to the cyclin D1 AP-1 motif in vitro. 3) In
vivo, binding of liganded ER to ERE was augmented by short
stimulation with IGF-1 (1 and 4 h), whereas ER binding to
AP-1 was not affected by IGF-1 cotreatment. 4) The addition
of IGF-1 to E2 increased the abundance of p300, Carm,
AcH3, and pol II at ERE at 1 h of treatment, which was
paralleled by augmented pS2 mRNA expression. 5) Cotreat-
ment with E2 and IGF-1 decreased the abundance of p300 on
AP-1 but did not significantly affect cyclin D1 mRNA
expression. 6) Stimulation with IGF-1 alone (1 h) increased
FIGURE 5—continued
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the assembly of the ERSRC-1p300E6LMdm2Carmpol II
complex on AP-1 but not on ERE. This was associated with
up-regulation of cyclin D1, but not pS2, mRNA levels. 7) ER
knockdown reduced the recruitment of ER and several ER
coregulators(E6L,Mdm2,Carm)toAP-1anddecreasedIGF-1-
dependent cyclin D1 mRNA transcription.
The stimulation of ER trafficking by IGF-1 could be
related to enhanced ER phosphorylation (5, 15, 57) and/or
direct interaction with IGF-1 signaling proteins like GSK-3,
which has been shown to promote ER nuclear translocation
in breast cancer cells (58). In our experiments, increased
levels of liganded ER in the presence of IGF-1 were observed
at 4 h of treatment but not evident at 1 h of stimulation,
perhaps due to limited sensitivity of detection by WB. How-
ever, IGF-1 augmented binding of liganded ER to ERE at 1 h
and 4 h, which suggests that IGF-1 not only can improve ER
nuclear translocation but also might facilitate the associa-
tion of ER with DNA, for instance by initiation of chromatin
modifications (Fig. 7). This suggestion is supported by our
observations that IGF-1 increased the levels of AcH3 at ERE
(Figs. 5A and 7). The addition of IGF-1 also augmented E2-
dependent recruitment of p300, Carm, and pol II. The
enhanced accumulation of these factors on ERE was proba-
bly related to a more efficient loading of liganded ER, since
IGF-1 alone did not affect these proteins (Figs. 5A and 7).
Thus, IGF-1 might potentiate E2-dependent transcription
by improving the recruitment of liganded ER and associated
proteins to ERE sites, at least at early time points.
A remarkably different picture can be seen at the cyclin D1
AP-1 site. This site has been shown to be indirectly activated
by ER in different cell models (30, 32, 56). Indeed, in our
experiments, liganded ER together with SRC-1, p300, E6L,
Mdm2, and pol II can be found on AP-1 (Figs. 5B and 7).
However, the presence of these proteins was correlated with
FIGURE 6. Effects of ER knockdown on IGF-1-induced cyclin D1 transcription. ER expression was down-regulated by RNA interference, as described under
“Experimental Procedures.” Nontargeting siRNA (C siRNA) was used as a control. The cells were transfected with ER siRNA or nontargeting siRNA or left
untreated in SFM. Then all populations were stimulatedwith IGF-1 for 1 h. The levels of ERwere assessed byWB (A), and the expression of cyclin D1mRNAwas
analyzed by quantitative real time PCR (B). The recruitment of ER and other transcriptional regulators to AP-1was studied by ChIP (C andD). Control ChIPswith
nonimmune IgG were negative (data not shown).
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only modest induction of cyclin D1 mRNA expression (Fig.
2). Furthermore, the addition of IGF-1 had no significant
effect on E2-stimulated cyclin D1 mRNA levels over a
1–24-h time course (Fig. 2 and data not shown). On AP-1,
IGF-1 reduced E2-dependent levels of p300 at 1 h, whereas at
later time points, IGF-1 increased the abundance of p300
and AcH3 but decreased the binding of SRC-1. The exact
mechanism of this phenomenon is unclear, but it could be
speculated that under combined E2 and IGF-1 treatment, at
least initially, the assembly of the fully active ER transcrip-
tional complex occurs preferentially at sites of direct ER
transcription (Fig. 7), which might be subsequently followed
by redistribution of ER cofactors to the sites of indirect ER
transcription. This would also implicate that some regula-
tory proteins, like p300 and SRC-1 that are common cofac-
tors for steroid receptors and AP-1 (59–61), must be shared
among several transcription sites. Notably, the recruitment
of p300 and SRC-1 was not sufficient for optimal transcrip-
tion (Fig. 7B), but their absence on ERE or AP-1 was usually
related to reduced transcription (Fig. 7A).
As expected, treatment with
IGF-1 alone stimulated the expres-
sion of cyclin D1 mRNA (38–40).
Under IGF-1, the transcriptional
complex on the cyclin D1 AP-1 site
included p300 and SRC-1, both of
which are required for cyclin D1
mRNA expression (32, 60). IGF-1
also induced the association of ER
and its coregulators Carm, Mdm2,
and E6L to the AP-1 site. ER knock-
down resulted in reduced loading
of ER, E6L, Mdm2, Carm, and pol
II to AP-1 in IGF-1-treated cells.
However, IGF-1 was still able to
stimulate the recruitment of p300
and SRC-1 to AP-1 and support
partial cyclin D1 expression (Figs.
6 and 7B).
IGF-1 was less capable in recruit-
ing the ER complex at ERE, where
only low amounts of ER, SRC-1, and
E6L were found (Figs. 5A and 6).
Interestingly, a long term (24-h)
IGF-1 treatment reduced ER abun-
dance at ERE possibly due to IGF-1-
dependent down-regulation of ER
(25).
In conclusion, our results dem-
onstrate for the first time that
IGF-1 and E2 differentially regu-
late the formation of transcrip-
tional complexes at ERE and AP-1
sites. The synergism between E2
and IGF-1 in the regulation of
gene transcription was noted for
liganded ER at ERE but not at AP-1
sites. The requirement for ER for
IGF-1-dependent transcription was documented for the
cyclin D1 AP-1 site.
REFERENCES
1. Aronica, S. M., and Katzenellenbogen, B. S. (1993) Mol. Endocrinol. 7,
743–752
2. Ignar-Trowbridge, D. M., Teng, C. T., Ross, K. A., Parker, M. G., Korach,
K. S., and McLachlan, J. A. (1993)Mol. Endocrinol. 7, 992–998
3. Reddy, K. B., Yee, D., Hilsenbeck, S. G., Coffey, R. J., and Osborne, C. K.
(1994) Cell Growth Differ. 5, 1275–1282
4. Ruohola, J. K., Valve, E. M., Karkkainen, M. J., Joukov, V., Alitalo, K., and
Harkonen, P. L. (1999)Mol. Cell Endocrinol. 149, 29–40
5. Surmacz, E. (2000) J. Mammary Gland Biol. Neoplasia 5, 95–105
6. Surmacz, E., and Bartucci, M. (2004) J. Exp. Clin. Cancer Res. 23, 385–394
7. Jerome, L., Shiry, L., and Leyland-Jones, B. (2004) Semin. Oncol. 31, Suppl.
3, 54–63
8. Edwards, D. P.,Weigel, N. L., Nordeen, S. K., and Beck, C. A. (1993) Breast
Cancer Res. Treat. 27, 41–56
9. Lange, C. A. (2004)Mol. Endocrinol. 18, 269–278
10. Lannigan, D. A. (2003) Steroids 68, 1–9
11. Shupnik, M. A. (2004) Oncogene 23, 7979–7989
12. Weigel, N. L., and Zhang, Y. (1998) J. Mol. Med. 76, 469–479
13. Stoica, A., Saceda, M., Fakhro, A., Joyner, M., and Martin, M. B. (2000)
FIGURE 7.Model of transcriptional regulation at the pS2 ERE and cyclin D1 AP-1 sites under E2 and/or
IGF-1 treatments. The model presented in A is based on the results obtained in this study and on previous
reports (32, 52, 59–63). The IGF-1-dependent regulation of the cyclin D1 AP-1 site in cells with ER knockdown
is shown in B.
E2/IGF-1 Cross-talk and ER-dependent Gene Transcription
FEBRUARY 9, 2007•VOLUME 282•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3505
 by guest, on April 27, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
J. Cell. Biochem. 76, 605–614
14. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali,
S., and Nakshatri, H. (2001) J. Biol. Chem. 276, 9817–9824
15. Martin,M. B., Franke, T. F., Stoica, G. E., Chambon, P., Katzenellenbogen,
B. S., Stoica, B. A., McLemore, M. S., Olivo, S. E., and Stoica, A. (2000)
Endocrinology 141, 4503–4511
16. Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M.,
Beato, M., Sica, V., Bresciani, F., and Weisz, A. (1996) Oncogene 12,
2315–2324
17. Lewis, J. S., Thomas, T. J., Pestell, R. G., Albanese, C., Gallo, M. A., and
Thomas, T. (2005) J. Mol. Endocrinol. 34, 91–105
18. Planas-Silva, M. D., and Weinberg, R. A. (1997) Mol. Cell. Biol. 17,
4059–4069
19. Prall, O. W., Sarcevic, B., Musgrove, E. A., Watts, C. K., and Sutherland,
R. L. (1997) J. Biol. Chem. 272, 10882–10894
20. McKenna, N. J., and O’Malley, B. W. (2002) Cell 108, 465–474
21. Metivier, R., Penot, G., Hubner, M. R., Reid, G., Brand, H., Kos, M., and
Gannon, F. (2003) Cell 115, 751–763
22. Shang, Y., Hu, X., DiRenzo, J., Lazar,M.A., andBrown,M. (2000)Cell 103,
843–852
23. Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D.,
Beaudouin, J., Ellenberg, J., and Gannon, F. (2003)Mol. Cell 11, 695–707
24. Krieg, A. J., Krieg, S. A., Ahn, B. S., and Shapiro, D. J. (2004) J. Biol. Chem.
279, 5025–5034
25. Stoica, A., Saceda, M., Doraiswamy, V. L., Coleman, C., andMartin, M. B.
(2000) J. Endocrinol. 165, 371–378
26. Roy, P. G., and Thompson, A. M. (2006) Breast 15, 718–727
27. Reis-Filho, J. S., Savage, K., Lambros, M. B., James, M., Steele, D., Jones,
R. L., and Dowsett, M. (2006)Mod. Pathol. 19, 999–1009
28. Yu, Q., Sicinska, E., Geng, Y., Ahnstrom, M., Zagozdzon, A., Kong, Y.,
Gardner, H., Kiyokawa, H., Harris, L. N., Stal, O., and Sicinski, P. (2006)
Cancer Cell 9, 23–32
29. Malara, N. M., Leotta, A., Sidoti, A., Lio, S., D’Angelo, R., Caparello, B.,
Munao, F., Pino, F., and Amato, A. (2006) Breast 15, 81–89
30. Shiozawa, T., Miyamoto, T., Kashima, H., Nakayama, K., Nikaido, T., and
Konishi, I. (2004) Oncogene 23, 8603–8610
31. Castro-Rivera, E., Samudio, I., and Safe, S. (2001) J. Biol. Chem. 276,
30853–30861
32. Cheung, E., Acevedo,M. L., Cole, P. A., and Kraus,W. L. (2005) Proc. Natl.
Acad. Sci. U. S. A. 102, 559–564
33. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht,
R. M., and Webb, P. (2000) J. Steroid Biochem. Mol. Biol. 74, 311–317
34. Kim, M. Y., Hsiao, S. J., and Kraus, W. L. (2001) EMBO J. 20, 6084–6094
35. Teyssier, C., Belguise, K., Galtier, F., Cavailles, V., and Chalbos, D. (2003)
Mol. Endocrinol. 17, 287–299
36. Hadsell, D. L., and Abdel-Fattah, G. (2001) Adv. Exp. Med. Biol. 501,
79–85
37. Strobl, J. S.,Wonderlin,W. F., and Flynn, D. C. (1995)Gen. Pharmacol. 26,
1643–1649
38. Zhang, S., Li, X., Burghardt, R., Smith, R., III, and Safe, S. H. (2005) J. Mol.
Endocrinol. 35, 433–447
39. Dufourny, B., van Teeffelen, H. A., Hamelers, I. H., Sussenbach, J. S., and
Steenbergh, P. H. (2000) J. Endocrinol. 166, 329–338
40. Butt, A. J., McNeil, C. M., Musgrove, E. A., and Sutherland, R. L. (2005)
Endocr. Relat. Cancer 12, Suppl. 1, 47–59
41. Hamelers, I. H., van Schaik, R. F., Sipkema, J., Sussenbach, J. S., and
Steenbergh, P. H. (2002) J. Biol. Chem. 277, 47645–47652
42. Hamelers, I. H., and Steenbergh, P. H. (2003) Endocr.-Relat. Cancer 10,
331–345
43. Varma, H., and Conrad, S. E. (2002) Cancer Res. 62, 3985–3991
44. Guvakova, M. A., and Surmacz, E. (1997) Exp. Cell Res. 231, 149–162
45. Salerno, M., Sisci, D., Mauro, L., Guvakova, M. A., Ando, S., and Surmacz,
E. (1999) Int. J. Cancer 81, 299–304
46. Morelli, C., Garofalo, C., Bartucci, M., and Surmacz, E. (2003) Oncogene
22, 4007–4016
47. Zhu, Y., Saunders,M.A., Yeh,H., Deng,W.G., andWu,K. K. (2002) J. Biol.
Chem. 277, 6923–6928
48. Morelli, C., Garofalo, C., Sisci, D., del Rincon, S., Cascio, S., Tu, X.,
Vecchione, A., Sauter, E. R., Miller, W. H., Jr., and Surmacz, E. (2004)
Oncogene 23, 7517–7526
49. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H.,
Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and
Chambon, P. (1995) Science 270, 1491–1494
50. Lee, A. V., Weng, C. N., Jackson, J. G., and Yee, D. (1997) J. Endocrinol.
152, 39–47
51. Yee, D., and Lee, A. V. (2000) J. Mammary Gland Biol. Neoplasia 5,
107–115
52. Klinge, C. M. (2000) Steroids 65, 227–251
53. McKenna, N. J., and O’Malley, B. W. (2002) Endocrinology 143,
2461–2465
54. Kushner, P. J., Agard, D., Feng,W. J., Lopez, G., Schiau, A., Uht, R., Webb,
P., and Greene, G. (2000) Novartis Found. Symp. 230, 20–40
55. Sachdev, D., and Yee, D. (2001) Endocr.-Relat. Cancer 8, 197–209
56. Philips, A., Chalbos, D., and Rochefort, H. (1993) J. Biol. Chem. 268,
14103–14108
57. Lee, A. V., Jackson, J. G., Gooch, J. L., Hilsenbeck, S. G., Coronado-
Heinsohn, E., Osborne, C. K., and Yee, D. (1999) Mol. Endocrinol. 13,
787–796
58. De Servi, B., Hermani, A., Medunjanin, S., andMayer, D. (2005)Oncogene
24, 4946–4955
59. Lee, S. K., Kim, H. J., Kim, J. W., and Lee, J. W. (1999)Mol. Endocrinol. 13,
1924–1933
60. Lee, S. K., Kim, H. J., Na, S. Y., Kim, T. S., Choi, H. S., Im, S. Y., and Lee,
J. W. (1998) J. Biol. Chem. 273, 16651–16654
61. Na, S. Y., Lee, S. K., Han, S. J., Choi, H. S., Im, S. Y., and Lee, J. W. (1998)
J. Biol. Chem. 273, 10831–10834
62. Bannister, A. J., Oehler, T., Wilhelm, D., Angel, P., and Kouzarides, T.
(1995) Oncogene 11, 2509–2514
63. Teyssier, C., Belguise, K., Galtier, F., and Chalbos, D. (2001) J. Biol. Chem.
276, 36361–36369
64. ABI (1997) ABI User Bulletin No. 2, ABI, Foster City, CA
E2/IGF-1 Cross-talk and ER-dependent Gene Transcription
3506 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 6•FEBRUARY 9, 2007
 by guest, on April 27, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
